Status:
UNKNOWN
Tetracycline to Limit the Innate Immune Response in Acute Respiratory Distress Syndrome
Lead Sponsor:
University of Bonn
Conditions:
Adult Respiratory Distress Syndrome
Pneumonia
Eligibility:
All Genders
18+ years
Brief Summary
The acute respiratory distress syndrome (ARDS) is a severe form of respiratory failure with a mortality rate of approximately 40%. Despite advances in its supportive treatment such as lung protective ...
Eligibility Criteria
Inclusion
- Age \> 18 years
- Informed consent of the patient
- Diagnosis of ARDS for \< 48 h
Exclusion
- Age \< 18 years
- Missing informed consent
- Immune therapy
- Autoimmune disease
Key Trial Info
Start Date :
January 4 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2022
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04079426
Start Date
January 4 2019
End Date
January 1 2022
Last Update
September 6 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Bonn
Bonn, Germany, 53127